Abstract: The invention relates to new peptide compounds capable of modulating cell proliferation, differentiation, survival and/or motility. The peptide compounds of the invention comprise short peptide fragments of the ErbB receptor and are capable of binding to ErbB and modulating activity of the receptor. The invention also relates to antibodies capable of binding to an epitope comprising a peptide sequence of the invention, pharmaceutical compositions comprising the peptide sequences and/or antibodies and uses thereof for treatment of conditions wherein modulating activity of ErbB is needed.
Type:
Grant
Filed:
April 3, 2007
Date of Patent:
March 1, 2011
Assignee:
Københavns Universitet
Inventors:
Elisabeth Bock, Vladimir Berezin, Gro Klitgaard Povlsen
Abstract: The present invention provides biomarkers for schizophrenic and bipolar disorders and methods of diagnosis, monitoring and screening associated with the biomarkers and kits for performing such methods.
Abstract: The current invention discloses nucleic acid and amino acid sequences for novel organic anion transfer proteins (“OATPs”). The invention encompasses the OATPs described herein, together with vectors containing the cDNA sequences, host cells containing the vectors and polypeptides having all or part of an OATP. Also encompasses are uses for OATPs for targeting drugs to specific organs and for modulating the concentration of endogenous substrates.
Type:
Grant
Filed:
May 17, 2007
Date of Patent:
September 14, 2010
Assignee:
Bristol-Myers Squibb Company
Inventors:
Todd G. Kirchgessner, Bonnie Hsiang, Yingjie Zhu, Yuli Wu, Zhaoqing Wang, Jean S. Lynch, Xin Huang, Wen-Pin Yang
Abstract: The invention relates to method of diagnosing Alzheimer's disease or detecting a predisposition to Alzheimer's disease including providing a test cell sample from a subject, exposing the test cell sample to labeled amyloid beta peptides, and determining the level of labeled amyloid beta peptides in the test cell sample, wherein lower levels of labeled amyloid beta peptides in the test cell sample compared to a control cell sample are indicative of Alzheimer's disease.
Type:
Grant
Filed:
October 19, 2007
Date of Patent:
August 10, 2010
Assignee:
The Regents of the University of California
Abstract: Embodiments are directed to a peptide and protein containing that peptide, nucleic acids, antibodies, as well assays detecting the peptide or protein, and methods of identifying patients with or at risk of developing Alzheimer's Disease and other neurodegenerative diseases.
Abstract: The present invention relates to phosphorylated tau protein epitopes associated with Alzheimer's disease, to protein kinases responsible for tau protein epitope phosphorylation, and to antibodies specific for the tau epitopes. Additionally, the present invention relates to pharmaceutical compositions, methods for detection, and methods of testing drugs effective in dissolving paired helical filaments associated with Alzheimer's disease.
Type:
Grant
Filed:
February 4, 2002
Date of Patent:
February 13, 2007
Assignee:
Max-Planck-Gesellschaft zur Forderungder Wissenshaften, E.V.
Inventors:
Eva-Marie Mandelkow, Eckhard Mandelkow, Birgit Lichtenberg-Kraag, Jacek Biernat, Gerard Drewes, Barbara Steiner
Abstract: Treatment and/or prophylaxis, in mammalian patients, of neurodegenerative and other neurological medical disorders is effected by administering to the patient effective amounts of apoptotic bodies and/or apoptotic cells, preferably those derived from the patient's own white blood cells, e.g. by extracorporeal treatment of the patient's blood cells to induce apoptosis and administration of the apoptotic bodies and/or cells so formed to the patient.
Type:
Grant
Filed:
May 25, 2001
Date of Patent:
November 7, 2006
Assignee:
Vasogen Ireland Limited
Inventors:
Anthony E. Bolton, Arkady Mandel, Daniel Sauder
Abstract: Nucleic acids encoding SOC/CRAC calcium channel polypeptides, including fragments and biologically functional variants thereof and encoded polypeptides are provided. The nucleic acids and polypeptides disclosed herein are useful as therapeutic and diagnostic agents. Agents that selectively bind to the foregoing polypeptides and genes also are provided.
Type:
Grant
Filed:
December 20, 1999
Date of Patent:
June 20, 2006
Assignee:
Beth Israel Deaconess Medical Center, Inc.